Seelos Therapeutics, Inc., a biotechnology company incorporated in Nevada, has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice for an offering with the first sale yet to occur, dated 05/21/2024. The filing, signed by Chief Financial Officer Michael Golembiewski on 05/31/2024, states that the total offering amount is $2,042,954 USD, with none sold yet. The offering includes options, warrants, or other rights to acquire securities, and the securities to be acquired upon the exercise of these options or warrants. The company has claimed an exemption under Rule 506(b) and does not intend the offering to last more than one year. Seelos Therapeutics has not generated any revenue and has not disclosed the use of proceeds for payments to its executive officers, directors, or promoters. The company has also appointed agents for service of process, indicating compliance with the SEC and state securities laws.

Seelos Therapeutics, Inc., a biotechnology company incorporated in Nevada, has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice for an offering with the first sale yet to occur, dated 05/21/2024. The filing, signed by Chief Financial Officer Michael Golembiewski on 05/31/2024, states that the total offering amount is $2,042,954 USD, with none sold yet. The offering includes options, warrants, or other rights to acquire securities, and the securities to be acquired upon the exercise of these options or warrants. The company has claimed an exemption under Rule 506(b) and does not intend the offering to last more than one year. Seelos Therapeutics has not generated any revenue and has not disclosed the use of proceeds for payments to its executive officers, directors, or promoters. The company has also appointed agents for service of process, indicating compliance with the SEC and state securities laws.